Logo image of XELB

XCEL BRANDS INC (XELB) Stock Fundamental Analysis

NASDAQ:XELB - US98400M2008 - Common Stock

1.36 USD
-0.04 (-2.86%)
Last: 8/29/2025, 8:00:09 PM
Fundamental Rating

2

Overall XELB gets a fundamental rating of 2 out of 10. We evaluated XELB against 123 industry peers in the Specialty Retail industry. XELB may be in some trouble as it scores bad on both profitability and health. XELB has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

XELB had negative earnings in the past year.
In the past year XELB has reported a negative cash flow from operations.
In the past 5 years XELB always reported negative net income.
In the past 5 years XELB reported 4 times negative operating cash flow.
XELB Yearly Net Income VS EBIT VS OCF VS FCFXELB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

XELB has a worse Return On Assets (-48.91%) than 91.87% of its industry peers.
Looking at the Return On Equity, with a value of -94.11%, XELB is doing worse than 73.17% of the companies in the same industry.
Industry RankSector Rank
ROA -48.91%
ROE -94.11%
ROIC N/A
ROA(3y)-25.19%
ROA(5y)-19.15%
ROE(3y)-40.45%
ROE(5y)-30.57%
ROIC(3y)N/A
ROIC(5y)N/A
XELB Yearly ROA, ROE, ROICXELB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

Looking at the Gross Margin, with a value of 135.33%, XELB belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Gross Margin of XELB has grown nicely.
XELB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 135.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.58%
GM growth 5Y4.65%
XELB Yearly Profit, Operating, Gross MarginsXELB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

2

2. Health

2.1 Basic Checks

XELB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XELB has less shares outstanding
XELB has less shares outstanding than it did 5 years ago.
XELB has a worse debt/assets ratio than last year.
XELB Yearly Shares OutstandingXELB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
XELB Yearly Total Debt VS Total AssetsXELB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -2.79, we must say that XELB is in the distress zone and has some risk of bankruptcy.
XELB has a Altman-Z score of -2.79. This is amonst the worse of the industry: XELB underperforms 84.55% of its industry peers.
A Debt/Equity ratio of 0.48 indicates that XELB is not too dependend on debt financing.
XELB has a Debt to Equity ratio (0.48) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z -2.79
ROIC/WACCN/A
WACC10.24%
XELB Yearly LT Debt VS Equity VS FCFXELB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

XELB has a Current Ratio of 0.59. This is a bad value and indicates that XELB is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.59, XELB is doing worse than 90.24% of the companies in the same industry.
A Quick Ratio of 0.59 indicates that XELB may have some problems paying its short term obligations.
The Quick ratio of XELB (0.59) is better than 60.16% of its industry peers.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.59
XELB Yearly Current Assets VS Current LiabilitesXELB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

XELB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.29%, which is quite impressive.
Looking at the last year, XELB shows a very negative growth in Revenue. The Revenue has decreased by -42.63% in the last year.
Measured over the past years, XELB shows a very negative growth in Revenue. The Revenue has been decreasing by -27.67% on average per year.
EPS 1Y (TTM)54.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-270%
Revenue 1Y (TTM)-42.63%
Revenue growth 3Y-39.84%
Revenue growth 5Y-27.67%
Sales Q2Q%-55.28%

3.2 Future

XELB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 46.07% yearly.
Based on estimates for the next years, XELB will show a very strong growth in Revenue. The Revenue will grow by 29.10% on average per year.
EPS Next Y50.56%
EPS Next 2Y46.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year38.35%
Revenue Next 2Y29.1%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XELB Yearly Revenue VS EstimatesXELB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
XELB Yearly EPS VS EstimatesXELB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 -4 -6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

XELB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 4.44, the valuation of XELB can be described as very cheap.
Based on the Price/Forward Earnings ratio, XELB is valued cheaply inside the industry as 99.19% of the companies are valued more expensively.
XELB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.76.
Industry RankSector Rank
PE N/A
Fwd PE 4.44
XELB Price Earnings VS Forward Price EarningsXELB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XELB Per share dataXELB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
XELB's earnings are expected to grow with 46.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.07%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XELB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XCEL BRANDS INC

NASDAQ:XELB (8/29/2025, 8:00:09 PM)

1.36

-0.04 (-2.86%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-13 2025-11-13/amc
Inst Owners20.05%
Inst Owner Change27.13%
Ins Owners39.9%
Ins Owner Change9.48%
Market Cap6.47M
Analysts82.86
Price Target8.16 (500%)
Short Float %4.81%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.03%
Min EPS beat(2)-3.39%
Max EPS beat(2)27.45%
EPS beat(4)3
Avg EPS beat(4)26.9%
Min EPS beat(4)-3.39%
Max EPS beat(4)54.75%
EPS beat(8)7
Avg EPS beat(8)36.96%
EPS beat(12)9
Avg EPS beat(12)23.28%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-36.32%
Min Revenue beat(2)-43.05%
Max Revenue beat(2)-29.58%
Revenue beat(4)1
Avg Revenue beat(4)-25.67%
Min Revenue beat(4)-43.05%
Max Revenue beat(4)7.72%
Revenue beat(8)1
Avg Revenue beat(8)-16%
Revenue beat(12)3
Avg Revenue beat(12)-8.58%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-40.74%
PT rev (3m)-54.29%
EPS NQ rev (1m)36.84%
EPS NQ rev (3m)-300%
EPS NY rev (1m)2.63%
EPS NY rev (3m)-101.82%
Revenue NQ rev (1m)-26.46%
Revenue NQ rev (3m)-47.28%
Revenue NY rev (1m)23.43%
Revenue NY rev (3m)-19.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 4.44
P/S 1.12
P/FCF N/A
P/OCF N/A
P/B 0.26
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.24
EYN/A
EPS(NY)0.31
Fwd EY22.5%
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS1.21
BVpS5.15
TBVpS-1.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.91%
ROE -94.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 135.33%
FCFM N/A
ROA(3y)-25.19%
ROA(5y)-19.15%
ROE(3y)-40.45%
ROE(5y)-30.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.58%
GM growth 5Y4.65%
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.5%
Cap/Sales 0.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.59
Quick Ratio 0.59
Altman-Z -2.79
F-Score3
WACC10.24%
ROIC/WACCN/A
Cap/Depr(3y)2.47%
Cap/Depr(5y)7.52%
Cap/Sales(3y)0.99%
Cap/Sales(5y)1.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-270%
EPS Next Y50.56%
EPS Next 2Y46.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-42.63%
Revenue growth 3Y-39.84%
Revenue growth 5Y-27.67%
Sales Q2Q%-55.28%
Revenue Next Year38.35%
Revenue Next 2Y29.1%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y46.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.74%
OCF growth 3YN/A
OCF growth 5YN/A